Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2019-05-10 Interim / Quarterly Rep…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BT_2019-05-10_Comptes Annuels 2018.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a formal Belgian 'Comptes Annuels' (Annual Accounts) filing for Bone Therapeutics. It contains detailed balance sheet data, identification of directors, and financial statements for the fiscal year 2018. While it is an annual document, it is a statutory filing of financial statements rather than a narrative 'Annual Report' (10-K) which typically includes management discussion, business strategy, and market outlook. In the context of European regulatory filings, these statutory financial statements are classified as Interim/Quarterly Reports (IR) when they represent the primary financial disclosure for the period, or as a general financial report. Given the specific definitions provided, this document serves as the comprehensive financial report for the fiscal year. FY 2018
2019-05-10 French
BT_2019-05-10_AGO_CV_Thomas LIENARD.pdf
Board/Management Information Classification · 99% confidence The document text is very short (912 characters) and exclusively details the professional background, experience, and career progression of an individual named Thomas Lienard, including his roles at Bone Therapeutics, Lundbeck, Eli Lilly, and McKinsey & Company. This content strongly suggests an announcement regarding a change in senior management or the board of directors, as it profiles a key executive. This aligns directly with the definition for Board/Management Information (MANG). It is not a financial report, earnings release, or a general regulatory filing.
2019-05-10 English
BT_2019-05-10_AGO_Convocation_FR.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "CONVOCATION À L'ASSEMBLÉE GÉNÉRALE ORDINAIRE" (Notice of Ordinary General Meeting) and details the agenda for a meeting scheduled for June 12, 2019. The agenda items include the submission and approval of annual accounts (for the year ended December 31, 2018), remuneration reports, director discharges, and the appointment/renewal of directors and the auditor. This content is characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-10 French
BT_2019-05-10_AGO_Convocation_EN.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'INVITATION TO THE ORDINARY GENERAL ASSEMBLY SHAREHOLDER'S MEETING TO BE HELD ON 12 JUNE 2019'. It details the agenda for this meeting, which includes the acknowledgment and approval of the 2018 annual accounts, the remuneration report, director discharges, director appointments/re-appointments, auditor re-appointment, and other resolutions related to remuneration and warrant plans. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM) to inform their voting decisions. Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-10 English
BT_Auditor Report-Bone Therapeutics SA-31Dec2018.pdf
Audit Report / Information Classification · 99% confidence The document is explicitly titled 'Rapport du commissaire à l'assemblée générale pour l'exercice clos le 31 décembre 2018' (Commissioner's report to the general meeting for the year ended December 31, 2018) and contains the 'Rapport sur l'audit des comptes annuels' (Report on the audit of the annual accounts) issued by Deloitte. This document is the formal, independent auditor's report accompanying the annual financial statements, which aligns perfectly with the definition of an Audit Report / Information (AR). Although it relates to the annual accounts, it is the auditor's opinion, not the full 10-K filing itself, nor is it merely an announcement of a report (RPA). FY 2018
2019-05-10 French
PR_2019-05-10_BT_AGO 2019 Notice_FR_Final.pdf
Report Publication Announcement Classification · 95% confidence The document is titled "Mise à disposition des documents préparatoires à l'assemblée générale ordinaire du 12 juin 2019" (Making available of preparatory documents for the Ordinary General Meeting of June 12, 2019). It explicitly states that the convocation and preparatory documents for the AGM are being made available to shareholders and can be consulted online or requested. This is an announcement about the availability of materials for an upcoming shareholder meeting, not the meeting materials themselves (like AGM-R) or the proxy statement (DEF 14A/PSI). Since it is an announcement regarding the availability/publication of documents related to a shareholder meeting, it fits best under Report Publication Announcement (RPA) or potentially Regulatory Filing (RNS) if RPA is too specific. Given the context of making documents available for an AGM, RPA is the most precise fit, as it announces the publication/availability of reports/documents.
2019-05-10 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.